http://www.actos.com/index.asp

 In Diabetes Today
http://tinyurl.com/hwabl
--------------------------------------------------------------------------------
04-SEP-2006 

Takeda Diabetes Drug Slashes Risk of Second Stroke


BARCELONA, Sept 3 (Reuters) - Patients with type 2 diabetes who have already
suffered a first stroke have 47 percent less risk of having a second one if they
take Takeda Pharmaceutical Co. Ltd's drug Actos, researchers said on Sunday. 

The finding, presented at the World Congress of Cardiology, is the latest sign
that the oral anti-diabetic medicine provides benefits beyond lowering blood
sugar levels. 

Dr Robert Wilcox of University Hospital, Nottingham, England, said adding Actos
to standard care reduced the incidence of secondary stroke by nearly half to 5.6
percent from 10.2 percent in this group of patients. 

There was, however, no effect of Actos on subsequent strokes in patients who had
never experienced a stroke. 

Actos, which is co-promoted by Eli Lilly and Co., belongs to a class of
medicines called insulin sensitisers that also includes GlaxoSmithKline Plc's
Avandia. 

They work by making the body's cells more sensitive to insulin, thereby helping
people with type 2, or adult-onset, diabetes to better use their own natural
insulin. 

The new research comes from analysis of a large clinical study called PROactive,
which first reported results a year ago. That found Actos reduced the risk of
heart attacks, strokes and death by 16 percent in all high-risk people with
diabetes. 

The initial study failed conclusively to show Actos prevented a broader range of
adverse events, including the need for leg surgery, which had been its primary
goal. 

Dr Robert Spanheimer, medical director for diabetes at Takeda, said he believed
doctors would be impressed by new data demonstrating such a large reduction in
the risk of second stroke. 

"This is amazing," he told Reuters. "When you classically think of stroke, you
think of blood pressure and maybe cholesterol. To think that a diabetes medicine
does this is truly remarkable." 

Copyright 2005 Reuters. Reuters content is the intellectual property of Reuters.
Any copying, republication or redistribution of Reuters content, including by
caching, framing or similar means, is expressly prohibited without the prior
written consent of Reuters. Reuters shall not be liable for any errors or delays
in content, or for any actions taken in reliance thereon. Reuters, the Reuters
Dotted Logo and the Sphere Logo are registered trademarks of the Reuters group
of companies around the world. 

-----------------------

To change your mail settings or leave the C-PALSY list, go here:

http://listserv.icors.org/SCRIPTS/WA-ICORS.EXE?SUBED1=c-palsy